Table IV.
Case | Direct sequencing | Scorpion-ARMS | Pyrosequencing | Luminex xMAP | DNA (ng/µl) without MD | DNA (ng/µl) with MD | ORR | PFS (days) | OS (days) |
---|---|---|---|---|---|---|---|---|---|
1 | NE | Wild | Wild | NE | 95.6 | 100.5 | SD | 83 | 157 |
2 | NE | Wild | NE | NE | 39.0 | 57.7 | SD | 383 | 740 |
3 | NE | NE | NE | NE | 26.6 | 56.2 | PR | 116 | 317 |
4 | NE | NE | NE | Wild | 2.1 | 4.3 | SD | 61 | 147 |
5 | NE | Wild | Wild | NE | 93.5 | 126.5 | PD | 17 | 95 |
NE, not evaluated; Wild, wild-type KRAS; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progression disease; MD, manual microdissection.